tbuckley/cabot-search huggingface dataset:
Ballinger and Wippern on the Eye, Ear, Nose and Throat. A Pocket Text-Book of Diseases of the Eye, Ear, Nose and Throat, for Students and Practitioners.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Gastrointestinal Tract
Authors: Anne Ferguson
Journal: Allergy (1995)

•Application of strict diagnostic criteria to celiac disease has led to the realization that there is a wide clinical spectrum within this disease. •Normally there are immune reactions to dietary proteins, particularly secretory antibodies of IgA class, low titers of serum antibody and specific down‐regulation of IgE and T cell reactivity (oral tolerance). •From time to time, abnormal immunity to foods, either as inappropriately high titers of antibodies or qualitatively altered responses, produce disease. •Lactase deficiency, with dose‐related lactose and milk‐intolerance, occurs in 50–90% of most populations. White, western Europeans are the exception.
Preferential attack on cancer by selected SH inhibitors
Authors: F. E. Knock
Journal: JAMA (1970)

<h3>To the Editor.—</h3> In sensitivity tests on hundreds of human cancers, selected sulfhydryl (SH) inhibitors have shown greater effect against tumors than against normal tissues. Clinically, SH inhibitors have caused the regression of a variety of human carcinomas, sarcomas, and lymphomas without injury to wound healing and with minimal injury to hematologic status and even improvement in some patients. The drug regimens are started within 24 to 48 hours of major cancer surgery, such as palliative bowel resection or pelvic exenteration. In two series totalling over 100 patients, the majority of patients whose tumors could be measured objectively received objective benefit from chemotherapy with the SH inhibitor oxophenarsine plus adjuncts, alone or in combination with other anticancer drugs which were picked in accord with sensitivity tests on each patient's own cancer.<sup>1</sup> From the work of Di Paolo<sup>2</sup>and Kondo<sup>3</sup>the sensitivity tests are now known to be
The Mattison Method in Morphinism. A Modern and Humane Treatment of the Morphin Disease.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Somatic Mutation As a Mechanism of Wnt/β-Catenin Pathway Activation in CLL
Authors: Lili Wang, Alex K Shalek, Jellert Gaublomme, Michael Lawrence, Kristen E. Stevenson, Donna S. Neuberg, Nir Hacohen, Gad Getz, Jennifer R. Brown, Hongkun Park, Catherine J. Wu
Journal: Blood (2012)
Abstract 5081: Leelamine is a novel inhibitor of fatty acid synthesis in prostate cancer
Authors: Krishna B. Singh, Shivendra V. Singh
Journal: Cancer Research (2019)

Abstract Increased beta-oxidation of fatty acids to meet energy demand is a rather unique characteristic of a subset of human prostate cancers. A safe and effective intervention for inhibition of fatty acid synthesis is still a clinically unmet need. We have shown previously that leelamine (LLM), a phytochemical derived from pine tree bark, suppresses expression and activity of full-length androgen receptor (AR) and its splice variants in vitro and in vivo in preclinical models of prostate cancer. Because AR is implicated in regulation of fatty acid metabolism, the present study was undertaken to determine the effect of LLM on this metabolic pathway. Treatment of a castration-resistant (22Rv1) as well as an androgen-responsive (LNCaP) human prostate cancer cell line with LLM (2.5 and 5 µmol/L) resulted in downregulation of key fatty acid synthesis enzyme proteins including ATP citrate lyase (ACLY), acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FASN), and sterol regulatory element-binding protein 1 (SREBP1). LLM treatment also decreased intracellular levels of total free fatty acids and neutral lipid droplets in LNCaP and 22Rv1 cells. Consistent with the in vitro results, we also observed a significant decrease in ACLY and SREBP1 protein expression and number of neutral lipid droplets in vivo in tumor tissue sections of 22Rv1 xenografts after intraperitoneal administration of LLM (9.1 mg/kg bw/ day, 5 times/week) compared to controls. Studies are in progress to determine if overexpression of AR and/or SREBP1 confers protection against fatty acid synthesis inhibition by LLM. In conclusion, it is reasonable to postulate that suppression of AR-SREBP1 regulated fatty acid metabolism is an important mechanism in prostate cancer inhibition by LLM. This study was supported by the grant RO1 CA101753 awarded by the National Cancer Institute. Citation Format: Krishna B. Singh, Shivendra V. Singh. Leelamine is a novel inhibitor of fatty acid synthesis in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5081.
Abstract 11988: Next Generation Sequencing of Cardiac Gene Expression Changes Associated With Heart Failure in Chronic Inflammation Inhibition
Authors: Takehiro Matsumoto, Atsuyuki Wada, Masanori Fujii, Atsuhi Taniguchi, Kousuke Mori, Yuichiro Tamagawa, Takahiro Isono, Minoru Horie
Journal: Circulation (2014)

Since a variety of gene alternations are involved in heart failure (HF), identifying key functional molecules associated with HF is a challenging task. Therefore, we investigated the global transcriptome analysis of left ventricle (LV) from tachycardia induced HF dogs using next generation genome sequencers. The mRNA sequence reads aligned with ~15000 of the 21407 genes using the human genome19 database. The analysis identified significantly up-regulated genes associated with inflammation such as Rel A, STAT 3, RIPK2, CDKN1, TNF-alpha, interleukin (IL) and p53 related pathways and collagen type 4, which regulate cell cycles of inflammatory cells and fibroblast. These data suggest chronic inflammation induced by those novel genes may affect cardiac remodelling and inhibition of these effects may become one of the strategies to treat HF. Thus, we focused on cardiac chymase activity that is stored in the mast cells recruited by stem cell factor and affects chronic inflammation closely linked with cardiac remodelling. We examined therapeutic effects of a chymase inhibitor (ChyI 0.3mg/kg/day, n=7) on cardiac structural changes and gene expressions in failing dogs’ heart. In HF, the number of chymase-degranulated cells evaluated by chymotrypsin staining increased in the LV compared with the normal group, however, ChyI significantly decreased that cell density. ChyI significantly suppressed the IL-6, Rel A, STAT 3, CDKN1, RIPK2, TNF-alpha and p-53 mRNA levels in the cardiac tissue. Not only collagen type 1,3 but also type 4 mRNA involved in maintaining the structural integrity were decreased compared with the vehicle. ChyI suppressed fibrosis in LV evaluated with picrosirius red stain (% collagen volume fraction; 1.1, Normal; 4.6, ChyI; vs 7.1%, Vehicle; P&lt;0.05, respectively). Despite no significant differences in blood pressure, ChyI shortened the prolongation of tau (22, Normal; 35, ChyI; vs 50 msec, Vehicle; P&lt;0.05, respectively) and decreased LV end-diastolic pressure. We can conclude that the global transcriptome analysis can provide new insights into cellular mechanisms and therapeutic effects of ChyI in HF.
Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. British Thoracic Society Research Committee.
Authors: Bhr Stack, D Geddes, K Williams, R Dinwiddie, J Selkon
Journal: Thorax (1985)

Abstract An open randomised comparison of a new intravenous cephalosporin, ceftazidime, with the established regimen of gentamicin and carbenicillin was carried out in patients with cystic fibrosis who had persisting pulmonary infection with Pseudomonas species and who developed acute exacerbations of respiratory symptoms. Fifty patients received ceftazidime and 32 gentamicin and carbenicillin. The ceftazidime and gentamicin were given every eight hours and the carbenicillin every six hours. The mean total daily doses were 151 mg/kg for ceftazidime, 6.3 mg/kg for gentamicin and 450 mg/kg for carbenicillin. The mean duration of treatment was 10 days in patients receiving gentamicin and carbenicillin and 12 days in those receiving ceftazidime. Of the patients with pseudomonas in the initial sputum specimen in whom sputum was cultured after treatment, six (26%) of 23 receiving gentamicin and carbenicillin and seven (18%) of 39 receiving ceftazidime had sputum free from pseudomonas at the end of treatment, but recolonisation occurred subsequently. In those receiving ceftazidime all 10 coexisting organisms were eliminated, whereas only four of seven coexisting organisms in patients receiving gentamicin and carbenicillin were eliminated. Overall clinical improvement occurred in 25 (78%) of 32 patients treated with gentamicin and carbenicillin and 48 (96%) of 50 patients treated with ceftazidime. Nineteen (59%) of the patients receiving gentamicin and carbenicillin but only 15 (30%) of those receiving ceftazidime required admission to hospital or intravenous antibiotics, or both, or died during the three months after treatment. Side effects in both groups were similar, mild, and infrequent. Thrombophlebitis occurred in four patients treated with gentamicin and carbenicillin but in no patients treated with ceftazidime.
Salute to the Clinical Pathologists
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase 2 study of oxaliplatin (O) -capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxane
Authors: N. Gebbia, F. Fulfaro, G. Badalamenti, C. Arcara, G. Cicero, G. Rinaldi, L. Vizzini, F. Spinnato, A. Russo, M. R. Valerio
Journal: Journal of Clinical Oncology (2004)

705 Background: O and C have showed an interesting activity as single agents in breast cancer patients. We carried out a phase II study to evaluate the efficacy and safety of combined O and C in anthracyclines and taxanes pretreated MBC patients. Methods: Eighteen MBC patients were treated with C 1,000 mg/sm bis in die per os, days 1 to 14 with a week of rest and O 130 mg/sm (2-hour intravenous infusion), day 1 every 3 weeks. Inclusion Criteria were: age <75, Performance Status (PS)</=2, normal kidney and liver function, absence of brain symptomatic metastases, at least two prior chemotherapy lines with anthracyclines and taxanes, informed consent. Mean age was 58 years (range, 33 to 74 years), with a median of two involved organs. Ten patients had a PS =0, 5 patients had a PS=1, 3 patients had a PS=2. The most frequent sites of disease were: liver (10 pts), skin (4 pts), bone (8 pts), pleura-lung (5 pts), lymphnodes (2 pts). Results: Fifteen patients were assessable for response and toxicity. According RECIST criteria 1 CR, 4 PR, 4 SD and 6 PD were obtained with an overall response rate of 33%. The partial responses occurred in patients with metastatic liver disease and the complete response occurred in a patient with cutaneous metastatic nodules and liver metastases. Median time to progression was 5.5 months (range 3–8 months) and median survival was 11.5 months (range 6–17 months) . Hematotoxicity was prevalent but rarely severe, with only 2 patients (13.3%) with G3 neutropenia and one (6.6%) patient with G3 thrombocytopenia. G1–2 neutropenia, anemia and thrombocytopenia occurred in 5 (33%), 3(20%), and 5 (33%) patients, respectively. One third of patients developed grade 2–3 peripheral neuropathy, with grade 3 in only 2 (13.3%) patients. Nausea & vomiting G1–2 and Diarrhea G1–2 were present in 6 patients. Hand-foot syndrome G2 occurred in 4 (26.6%) patients. Conclusions: From these preliminary data O/C combination seems to be effective with a favorable safety profile in anthracycline/taxane-pretreated MBC patients. No significant financial relationships to disclose.
TEST TUBE VACCINES
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tuberculosis of the mandible presenting as 'lumpy jaw'
Authors: R. B. Addlestone
Journal: JAMA (1979)

TUBERCULOSIS of the mandible has been diagnosed infrequently since the advent of effective antituberculosis medication. Initially, localized swelling of the jaw may be considered to represent pyogenic abscess or confused with actinomycosis of the mandible ("lumpy jaw"). We describe here a recent case in which a tuberculous cystic lesion of the mandible was initially misdiagnosed as "lumpy jaw." <h3>Report of a Case</h3> An 18-year-old, black college student was hospitalized with a six-week history of a swollen left jaw and a one-week history of a "lump" on the right leg. She had experienced pain around a wisdom tooth prior to the jaw swelling. Approximately four weeks prior to admission, she began taking oral penicillin G potassium as prescribed by her dentist. Approximately one week prior to admission, she noted a localized swelling and tenderness over the lateral aspect of the proximal end of the right lower leg. Three days prior to
Tcl1 Expression in Chronic Lymphocytic Leukemia Is Regulated by <i>miR-29</i> and <i>miR-181</i>
Authors: Yuri Pekarsky, Urmila Santanam, Amelia Cimmino, Alexey Palamarchuk, Alexey Efanov, Vadim Maximov, Stefano Volinia, Hansjuerg Alder, Chang-Gong Liu, Laura Rassenti, George A. Calin, John P. Hagan, Thomas Kipps, Carlo M. Croce
Journal: Cancer Research (2006)

Abstract B-cell chronic lymphocytic leukemia (B-CLL) is the most common human leukemia in the world. Deregulation of the TCL1 oncogene is a causal event in the pathogenesis of the aggressive form of this disease as was verified by using animal models. To study the mechanism of Tcl1 regulation in CLL, we carried out microRNA expression profiling of three types of CLL: indolent CLL, aggressive CLL, and aggressive CLL showing 11q deletion. We identified distinct microRNA signatures corresponding to each group of CLL. We further determined that Tcl1 expression is regulated by miR-29 and miR-181, two microRNAs differentially expressed in CLL. Expression levels of miR-29 and miR-181 generally inversely correlated with Tcl1 expression in the CLL samples we examined. Our results suggest that Tcl1 expression in CLL is, at least in part, regulated by miR-29 and miR-181 and that these microRNAs may be candidates for therapeutic agents in CLLs overexpressing Tcl1. (Cancer Res 2006; 66(24): 11590-3)
Racial Inequities in Kidney Transplantation: The UNOS Perspective-Reply
Authors: Robert S. Gaston
Journal: JAMA (1994)

<h3>In Reply.</h3> —Dr Norman misinterprets the premise of our article. Racial inequities in kidney transplantation are not perceived, but real, and waiting time is not the only aspect of the problem.<sup>1</sup>We do not contend that HLA-based allocation is wholly responsible, only that it is a significant, relatively unacknowledged contributing factor, and that its extension to a nationwide rather than local level would be disastrous for black patients. Even the UNOS statistics presented in Norman's letter offer added support for our position: between 1987 and 1992, white recipients were at least twice as likely as black recipients to have received an extremely well-matched kidney (10, seven, or six points). We restate our support for the current six-antigen match program: it enhances graft survival and removes relatively few kidneys from the overall cadaveric pool, and despite the overwhelming racial difference in allocation of such organs, it should be retained. However,
Occupational Medicine
Authors: Bruce W. Karrh
Journal: JAMA (1981)

The last year has presented many new challenges to occupational medicine. Three of these issues—third-party access to medical records, reproductive hazards in the workplace, and chronic illnesses that could be of occupational origin—will have as much impact on all aspects of medicine, irrespective of specialty, as on the practice of occupational medicine. Jermyn F. McCahan, MD, in the CONTEMPO '80 issue ofThe Journal, discussed the Occupational Safety and Health Administration (OSHA) Act and its effect on the practice of occupational medicine. Dr McCahan pointed out that OSHA has long been recognized as potentially having a significant effect on the practice of medicine outside the realm of occupational medicine and on the physician-patient relationship. <h3>Third-Party Access to Medical Records</h3> On May 23, 1980, OSHA published in the<i>Federal Register</i>its standard on access to employee exposure and medical records.<sup>1</sup>The agency states: the fundamental reasons for this standard are
Word Error and Incorrect/Omitted References in: Inadequacy of BMI as an Indicator for Bariatric Surgery
Authors: Hooman Kamel, Babak Navi, Jahan Fahimi, Fahimi Kamel
Journal: JAMA (2012)

Several factors may explain static ambulance use since the approval of time-sensitive therapy for ischemic stroke.Educational efforts may not be adequately addressing poor public knowledge about stroke, additional behavioral barriers may remain among those with adequate knowledge, or the response of health care providers to patients with stroke symptoms may be imperfect. 3Our findings suggest that national efforts to address barriers to ambulance use among patients with stroke need to be intensified or adjusted.
Misspelling and Incorrect Word
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1946)

Payment in a National Service SIR,-With reference to the remuneration to be received by general practitioners under the State scheme there appears to be a grave objection to acceptance of the capitation fee system.If it is intended to double the number of practitioners to pro- vide an efficient service, then surely the average income of doctors will eventually be halved, and most of us will face a steadily decreasing income instead of a gradual increase as is usual in all other walks of life.Perhaps such an obvious point has been raised previously, but if not I would be glad if publicity could be given to the matter.-Iam, etc.,